$ANIX News

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know

Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer

Anixa Biosciences secures Korean patent for breast cancer vaccine

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine Technology

/C O R R E C T I O N -- Anixa Biosciences, Inc./

Anixa Biosciences Announces Its Data From Phase 1 Clinical Study Of Liraltagene Autoleucel Demonstrates No Dose-Limiting Toxicities To Treat Recurrent Ovarian Cancer

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Receives Patent From Mexican Institute Of Industrial Property For Its Breast Cancer Vaccine Technology

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

Anixa Biosciences Reports Survival Data For Lira-cel In Phase 1 Trial At ISCT 2026 Conference